Hypertrophic Cardiomyopathy Podcast Series American Heart Association

In this On Demand video, Dr. Steve Ommen and Dr. Carolyn Ho discuss recent updates to the 2024 Guideline for the Management of Hypertrophic Cardiomyopathy (HCM). Watch now to enhance your knowledge on the importance of shared decision-making, the use of cardiac myosin inhibitors to treat symptomatic obstructive HCM, and risk stratification for atrial fibrillation to improve patient outcomes.

It is estimated that 1 in every 500 adults living in the U.S. have HCM, but a large percentage of patients are undiagnosed.  Listen to this podcast to gain insight into hypertrophic cardiomyopathy (HCM) screening and what it means to your patients.

Making the correct of hypertrophic cardiomyopathy (HCM) is critical in being able to initiate early surveillance and therapy to improve patient outcomes.  In this podcast focusing on pharmacologic treatment options, learn more about completed and ongoing myosin inhibitor clinical trials.

Accurate diagnosis of Hypertrophic Cardiomyopathy (HCM) is critical. HCM is a chronic and progressive disease putting patients at risk of serious complications and co-morbidities.  Early and correct detection may help reduce some of the consequences of HCM and improve outcomes. In this podcast, learn more about how to distinguish phenocopies from HCM.

Diagnosis of hypertrophic cardiomyopathy is typically done by echocardiogram to assess the thickness of the heart muscle and observe blood flow in and out of the heart. In this podcast, learn more about how echocardiography is used in the diagnosis, screening, and management of HCM.

Hypertrophic cardiomyopathy (HCM) is the most common form of inherited heart disease and can affect people of any age. In this episode, learn what causes hypertrophic cardiomyopathy in children and the clinical and genetic screening needed to diagnosis HCM.